Treatment with Varumin®

Varumin® is a herbal anticancer remedy for oral administration, which is consisted of two formulations: Varumin® 1 and Varumin® 2, for use in combination.

Activity

The extracts from herbal drugs, contained in Varumin® have wide spectrum of pharmacodynamic action. These components are widely applied in the traditional, homeopathic as well as in scientific medicine. The most significant pharmacodynamic actions of the components are: cytotoxic, immune-stimulative, detoxificative, anti-inflammatory, anti-microbe, diuretic, anti-depressive and laxative. Because of this, Varumin® can be used as adjuvant in standard therapy of different types of diseases, characterized with disordered immune system and bad general state.
There is no evidence of undesired effects as consequence of application of Varumin®.

Precautions

Varumin® should not be used: By persons hypersensitive to some components of the preparation; By persons with intestinal obstruction; By persons with existing inflammatory intestinal illnesses (Crohn’s disease, ulcerative colitis); By persons with inflammation of the appendix (appendicitis); By persons with hyperthyroidism; During pregnancy and lactation. Children under 10 years should take preparation with specific dosing regime. In these cases Varumin® can be used only by doctor’s or pharmacist’s recommendation.

Side effects

Long-term use of Varumin®, in very rare cases, can lead to diarrhea. There is no evidence of undesired effects as consequence of application of Varumin®.

Interactions

There are several effects because of use of aloe, but during the experience with Varumin® there is no evidence of interactions. Viscum album can stress the effect of the cardiac glycosides, hypotensive and hypertensive drugs, antidepressives and anticoagulants.

Indications

Varumin® improves the general state of the body when the organism is exhausted, for improving resistance of organism, as adjuvant in standard therapy of some acute and chronic diseases, malignant diseases, anaemia and other states that are characterized with low immunity and bad general condition. Varumin® can also be used as prevention against mentioned diseases.

Dosage

Varumin® is intended for oral use, by following schedule:
Beginning of the treatment – The therapy begins with Varumin® 1: Drink the whole amount of Varumin® 1 (50 ml), 1 hour before meal.
Continuation of the treatment – 6 hours after taking Varumin® 1, begin to take Varumin® 2. Varumin® 2 usually should be given four times a day, one soupspoon 1 hour before meal.

Shelf life

36 months from the date of production. Should not be used after the expiry date printed on the package.

Storage

Should be kept at temperature up to 25° C, protected from light.
Keep out of the reach of children!

Presentation

Varumin® 1 Glass bottle containing 50 ml solution for oral use. Varumin® 2 Glass bottle containing 200 ml solution for oral use.

Dispensing status

Country specific.

Cancer may affect people at all ages, even fetuses, but risk for the more common varieties tends to increase with age. Cancer causes about 13% of all deaths. According to the American Cancer Society, 7.6 million people died from cancer in the world during 2007.

Varumin® is a herbal anticancer remedy for oral administration, which is consisted of two formulations: Varumin® 1 and Varumin® 2, for use in combination.

Varumin® is designed in 1985 and was first approved in 2001. Varumin® is currently marketed in over 10 countries. Varumin® is indicated solely or in combination with another anticancer drug, according to the case, for the treatment of all types of cancer in both the early stages (adjuvant treatment) and in the metastatic phase.

Due to its herbal composition, the mechanism by which Varumin® exerts antitumor activity is not clear understood. However, it is believed that Varumin® has more different mechanisms of action, and the result is synergistic modulation of the host immune response, antiproliferative action against tumor cells and several other actions. Varumin® has remarkable efficacy coupled with excellent safety profile.

In Macedonia a broad clinical study program has conducted with the National Clinical Center and large cooperative groups work on determining and understanding of the benefits provided by Varumin® in the treatment of cervical cancer induced by HPV (human papilloma virus), and other cancers.

The conclusion from all made examinations is that Varumin® relieves the acceptance of standard therapy of malignant diseases, and has action by itself against cancer cells. Varumin® increases the resistance of the organism, and controls the immune response. With application of Varumin® it is expected fastened regeneration of destroyed tissues and complete recovery of the patient.

X